This clinical trial investigated the combined effects of Semaglutide and a fiber supplement (glucomannan, inulin, psyllium) on weight loss in adults with overweight or obesity. Participants, aged 18-65 with a BMI ≥30 or ≥27 with comorbidities, were randomized into two groups: one receiving Semaglutide with active fiber supplements and the other with Semaglutide and placebo, over a 180-day period. Key endpoints included percentage change in body weight, BMI, body composition, safety, and appetite control, with a focus on evaluating the additive effects of dietary fibers in enhancing Semaglutide's efficacy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
81
Semaglutide (2.4 mg weekly). Three daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.
Semaglutide (2.4 mg weekly). Three daily packets of placebo powder, taken 30 minutes before each main meal.
Center of New Medical Technologies
Novosibirsk, Novosibisk Region, Russia
Percentage change in body weight from baseline
Time frame: 180 days
Achievement of a reduction in body weight of 5% or more from baseline.
Time frame: 180 days
BMI change
Time frame: 180 days
fat mass change
fat mass change assessed using bioelectrical impedance analysis
Time frame: 180 day
Safety evaluated by recording any adverse events.
Time frame: 180 days
fat-free mass change
fat-free mass change assessed using bioelectrical impedance analysis
Time frame: 180 days
visceral fat rating change
visceral fat rating change assessed using bioelectrical impedance analysis
Time frame: 180 days
total body water change
total body water change assessed using bioelectrical impedance analysis
Time frame: 180 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.